Thomas Edward Leggett
Chief Financial OfficerMr. Thomas Edward Leggett, also known as Tommy, serves as Chief Financial Officer of Stoke Therapeutics, Inc. since April 2024. He served as Chief Financial Officer of Affinia Therapeutics, Inc. since December 2021 until 2025. He joined Affinia Therapeutics, Inc. in December 2021. He has been Independent Director at Research Alliance Corp. II since March 2021. Mr. Leggett had been the Chief Financial Officer at Black Diamond Therapeutics, Inc. (also known as Aset Therapeutics, Inc.) since September 2019 until November 16, 2021. He oversaw Black Diamond's financial strategy, Investor Relations, corporate communications, financial operations, financial planning & analysis and portfolio strategy and analytics. He has financial experience and has led and secured financing for dozens of life science companies. He is Independent Non-Executive Director at Clover Biopharmaceuticals, Ltd. since September 26, 2021. He served as Senior Vice President of Finance and Chief Financial Officer at Axcella Health, Inc. since January 3, 2017 until August 2019. Mr. Leggett served as the Head of Business Development Finance and Treasurer of Purdue Pharma since May 2016 to December 2017. Mr. Leggett joined Purdue Pharma with a broad range of investment banking experience and was an Executive Director and one of three senior calling officers leading the biopharmaceutical investment banking coverage effort in the Americas at UBS Securities LLC from November 2009 to April 2016. He served as a Vice President at Lazard Freres & Company. He worked in healthcare investment banking at Lazard Freres & Company and J.P. Morgan Securities Inc. Mr. Leggett was an Executive Director at UBS Securities LLC, an investment bank, in the Global Healthcare Group with a primary focus in the biopharmaceutical sector. He has multi-disciplinary experience leading, obtaining financing for and advising life science companies. He holds a Master of Business Administration in Finance from The Wharton School at the University of Pennsylvania and earned his Bachelor of Arts in Economics from Columbia University.
Positions
- Company NameStoke Therapeutics, Inc.Stock CodeSTOKPositionChief Financial OfficerColleagues
- IFIan F. SmithCEO & Director
- AOArthur O. TzianabosChairman of the Board
- ARAdrian R. KrainerCo-Founder & Independent Director
- TEThomas Edward LeggettChief Financial Officer
- JHJason HoittChief Patient Officer
- IAIsabel AznarezCo-Founder & CTO
- AAArthur A. LevinIndependent Director
- JCJennifer C. BursteinIndependent Director
- Company NameClover Biopharmaceuticals, Ltd.Stock Code02197PositionIndependent Non-Executive DirectorColleagues
- PLPeng LiangFounder, Chief Scientific Officer & Chairman of the Board
- JGJoshua G. LiangCEO & Executive Director
- YLYang LiChief Technology Officer
- HHHtay Htay HanChief Medical Officer of Vaccine
- BMBerry MichaelChief Technical Operation Officer
- XWXiaobin WuIndependent Non-Executive Director
- XWXiaodong WangNon-Executive Director
